2022-18801. Agency Information Collection Activities: Proposed Collection; Comment Request  

  • Start Preamble

    In compliance with Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 concerning opportunity for public comment on proposed collections of information, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the information collection plans, call the SAMHSA Reports Clearance Officer on (240) 276-0361.

    Comments are invited on: (a) whether the proposed collections of information are necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

    Proposed Project: “Notification of Intent To Use Schedule III, IV, or V Controlled Medications for the Treatment of Opioid Use Disorder” Under 21 U.S.C. 823(g)(2) (OMB No. 0930-0234 and OMB No. 0930-0369)—Revision

    The Drug Addiction Treatment Act of 2000 (“DATA,” Pub. L. 106-310) amended the Controlled Substances Act (21 U.S.C. 823(g)(2)) to permit qualifying practitioners to seek and obtain waivers to prescribe certain approved controlled medications for the treatment of opioid use disorder. The legislation set eligibility and certification requirements as well as an interagency notification review process for practitioners who seek waivers. To implement these provisions, SAMHSA developed Notification of Intent Forms that facilitate the submission and review of notifications.

    On October 24, 2018, the Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act (Pub. L. 115-71) was signed into law. Sections 3201-3202 of the SUPPORT Act made several amendments to the Controlled Substances Act regarding office-based opioid use disorder treatment that affords practitioners greater flexibility in the provision of Medications for Opioid Use Disorder (MOUD).

    The SUPPORT Act expands the definition of “qualifying other practitioner” enabling Clinical Nurse Specialists, Certified Registered Nurse Anesthetists, and Certified Nurse Midwives (CNSs, CRNAs, and CNMs) to apply for a Drug Addiction Treatment Act of 2000 (DATA) waiver. It also allows qualified practitioners ( i.e., MDs, DOs, NPs, PAs, CNSs, CRNAs, and CNMs) who are board certified in addiction medicine or addiction psychiatry, -or- practitioners who provide MOUD in a qualified practice setting, to start treating up to 100 patients in the first year of MOUD Start Printed Page 53481 practice (as defined in 42 CFR 8.2) with a waiver.

    Further, the SUPPORT Act extends the ability to treat up to 275 patients to “qualifying other practitioners” ( i.e., NPs, PAs, CNSs, CRNAs, and CNMs) if they have a waiver to treat up 100 patients for at least one year and provide MOUD with covered medications (as such terms are defined under 42 CFR 8.2) in a qualified practice setting as described under 42 CFR 8.615.

    Finally, the SUPPORT Act also expands how physicians could qualify for a waiver. Under the statute now, physicians can qualify for a waiver if they have received at least 8 hours of training on treating and managing patients with opioid use disorder, as listed in the statute if the physician graduated in good standing from an accredited school of allopathic medicine or osteopathic medicine in the United States during the 5-year period immediately preceding the date on which the physician submits a Notice of Intent to SAMHSA. In order to expedite the new provisions of the SUPPORT Act, SAMHSA sought and received a Public Health Emergency Paperwork Reduction Act Waiver.

    On April 28, 2021 the Department of Health and Human Services (HHS) issued the new Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder (86 FR 22439) in an expedited manner. The new Practice Guidelines allow practitioners who wish to obtain a 30-patient waiver to forego the 8-hour training requirement for physicians and 24-hour training for other qualifying practitioners. Practitioners utilizing this training exemption are limited to treating no more than 30-patients at a time and time spent practicing under this exemption will not qualify the practitioner to qualify for a higher patient level. In addition, the new Practice Guidelines removed the requirement to provide counseling and other ancillary services ( i.e., psychosocial services).

    The collection of information within the application is essential to the implementation of SAMHSA's mission to reduce the impact of substance use disorders on America's communities. Practitioners may use these forms for various types of notifications: (a) New Notification to treat up to 30 patients with training or without training; (b) New Notification, with the intent to immediately facilitate treatment of an individual (one) patient; (c) Second notification of need and intent to treat up to 100 patients; (d) New notification to treat up to 100 patients, and (e) New notification to treat up to 275 patients. The forms provide the information necessary to determine whether practitioners meet the qualifications for waivers set forth under the law at the 30E-, 30-, 100-, 275E-, and 275-patient limits. This includes the annual reporting requirements for practitioners with waivers for a 275-patient limit.

    Under “new” notifications, practitioners may make their initial waiver requests to SAMHSA. “Immediate” notifications inform SAMHSA and the Attorney General of a practitioner's intent to prescribe immediately to facilitate the treatment of an individual (one) patient under 21 U.S.C. 823(g)(2)(E)(ii). The form collects data on the following items: Practitioner name; state medical license number; medical specialty; and DEA registration number; address of primary practice location, telephone and fax numbers; email address; purpose of notification: new, immediate, or renewal; certification of qualifying criteria for treatment and management of patients with opioid use disorder; certification of capacity to provide directly or refer patients for appropriate counseling and other appropriate ancillary services, as applicable; certification of maximum patient load, certification to use only those medication formulations that meet the criteria in the law. The form also notifies practitioners of Privacy Act considerations and permits practitioners to expressly consent to disclose limited information to the SAMHSA Buprenorphine Physician and Behavioral Health Treatment Services locators. The following table summarizes the estimated annual burden for the use of this form.

    42 CFR citationPurpose of submissionEstimated number of respondentsResponses/ respondentBurden/ response (hr.)Total burden (hrs.)
    Notification of Intent1,80010.083149
    Notification to Prescribe Immediately6010.0835
    Notice to Treat up to 100 patients60010.0424
    Notice to Treat up to 275 patients96010.08178
    Subtotal3,420256
    Burden Associated With the Final Rule That Increased the Patient Limit
    8.620 (a)-(c)Request for Patient Limit Increase *62010.5310
    Request for Patient Limit Increase *62010.5310
    Request for Patient Limit Increase *62010.5310
    8.64Renewal Request for a Patient Limit Increase *31210.5156
    Renewal Request for a Patient Limit Increase *31210.5156
    Renewal Request for a Patient Limit Increase *31210.5156
    8.655Request for a Temporary Patient Increase for an Emergency *121336
    Request for a Temporary Patient Increase for an Emergency *121336
    Request for a Temporary Patient Increase for an Emergency *121336
    Subtotal2,4971,279
    Burden Associated With the Final Rule That Outlined the Reporting Requirements
    8.635Practitioner Reporting Form *1,620134,860
    “Qualifying Other Practitioner” under 21 USC § 823(g)(2)—Nurse Practitioners97910.06665
    Start Printed Page 53482
    “Qualifying Other Practitioner” under 21 USC § 823(g)(2)—Physician Assistants70810.06647
    “Qualifying Other Practitioner” under 21 USC § 823(g)(2)—Certified Nurse Specialists70810.06647
    “Qualifying Other Practitioner” under 21 USC § 823(g)(2)—Certified Nurse Mid-Wives70810.06647
    “Qualifying Other Practitioner” under 21 USC § 823(g)(2)—Certified Registered Nurse Anesthetists70810.06647
    Sub Total5,4315,112
    Total Burden6,5616,647

    Send comments to Carlos Graham, SAMHSA Reports Clearance Officer, 5600 Fishers Lane, Room 15E57-A, Rockville, Maryland 20857, OR email a copy to Carlos.Graham@samhsa.hhs.gov. Written comments should be received by October 31, 2022.

    Start Signature

    Carlos Graham,

    Reports Clearance Officer.

    End Signature End Preamble

    [FR Doc. 2022-18801 Filed 8-30-22; 8:45 am]

    BILLING CODE 4162-20-P

Document Information

Published:
08/31/2022
Department:
Substance Abuse and Mental Health Services Administration
Entry Type:
Notice
Document Number:
2022-18801
Pages:
53480-53482 (3 pages)
PDF File:
2022-18801.pdf